Eszopiclone

Generic Name
Eszopiclone
Brand Names
Lunesta
Drug Type
Small Molecule
Chemical Formula
C17H17ClN6O3
CAS Number
138729-47-2
Unique Ingredient Identifier
UZX80K71OE
Background

Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as cyclopyrrolones. Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia.
...

Indication

Eszopiclone is indicated for the treatment of insomnia.

Associated Conditions
Insomnia
Associated Therapies
-
Clinical Trials
Related News

Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study

First Posted Date
2007-08-13
Last Posted Date
2013-03-29
Lead Sponsor
University of Minnesota
Target Recruit Count
30
Registration Number
NCT00515177
Locations
🇺🇸

Minnesota Regional Sleep Disorders Center at Hennepin County Medical Center, Minneapolis, Minnesota, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

Phase 4
Terminated
Conditions
Insomnia
Nicotine Dependence
Interventions
Drug: Eszopiclone
Drug: Bupropion
First Posted Date
2007-08-03
Last Posted Date
2022-05-09
Lead Sponsor
Yale University
Target Recruit Count
4
Registration Number
NCT00511134
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

Ezopiclone Improves the Quality of Overnight Polysomnography

Phase 4
Completed
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Lunesta
Drug: Placebo control
First Posted Date
2007-07-25
Last Posted Date
2007-11-30
Lead Sponsor
Walter Reed Army Medical Center
Target Recruit Count
300
Registration Number
NCT00507117
Locations
🇺🇸

Walter Reed Army Medical Center, Washington DC, District of Columbia, United States

Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients

Phase 4
Completed
Conditions
Poor Quality Sleep
Interventions
Drug: Lunesta
First Posted Date
2007-04-17
Last Posted Date
2014-07-15
Lead Sponsor
Emory University
Target Recruit Count
71
Registration Number
NCT00460993

A Study of Eszopiclone Co-administered With Venlafaxine in Subjects With Major Depressive Disorder and Insomnia

First Posted Date
2007-02-14
Last Posted Date
2012-02-22
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
678
Registration Number
NCT00435279

How do Sleeping Pills Affect Pain in the Brain?

Phase 4
Terminated
Conditions
Primary Insomnia
Interventions
Drug: Placebo
Drug: Eszopiclone
First Posted Date
2006-12-21
Last Posted Date
2015-10-26
Lead Sponsor
University of California, San Diego
Target Recruit Count
40
Registration Number
NCT00414037
Locations
🇺🇸

UCSD Department of Psychiatry, Laboratory of Biological Dynamics and Theoretical Medicine, La Jolla, California, United States

Eszopiclone in the Treatment of Insomnia and Fibromyalgia

Phase 4
Completed
Conditions
Fibromyalgia
Insomnia
Interventions
Drug: Eszopiclone
Drug: placebo
First Posted Date
2006-10-25
Last Posted Date
2021-01-05
Lead Sponsor
Lesley A. Allen, Ph.D.
Target Recruit Count
36
Registration Number
NCT00392041
Locations
🇺🇸

Department of Psychiatry, UMDNJ-Robert Wood Johnson Medical School, Piscataway, New Jersey, United States

A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia

Phase 4
Completed
Conditions
Insomnia
Interventions
Drug: Placebo
Drug: Eszopiclone
First Posted Date
2006-10-11
Last Posted Date
2016-03-14
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
388
Registration Number
NCT00386334
Locations
🇺🇸

Anderson Pharmaceutical Research, Anderson, South Carolina, United States

The Treatment of Insomnia in Symptomatic Peri- and Postmenopausal Women

Not Applicable
Completed
Conditions
Menopause
Insomnia
Interventions
Drug: Eszopiclone
Drug: Placebo
First Posted Date
2006-09-11
Last Posted Date
2009-08-10
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
67
Registration Number
NCT00374192
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Insomnia and Osteoarthritis Study

Not Applicable
Completed
Conditions
Osteoarthritis
Insomnia
Interventions
Drug: Eszopiclone
Drug: Placebo
First Posted Date
2006-09-11
Last Posted Date
2019-03-14
Lead Sponsor
Johns Hopkins University
Target Recruit Count
30
Registration Number
NCT00374556
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy